# July 16, 2015

Ventana Medical Systems, Inc. Yassine Labiad, MS, RAC Regulatory Affairs Manager 203 Ravendale Drive Mountain View, CA 94043

Re: K142965 Trade/Device Name: Virtuoso‚Ñ¢ System for IHC PR (1E2) using the VENTANA iScan HT Regulation Number: 21 CFR $\$ 864.1860$ Regulation Name: Immunohistochemistry reagents and kits Regulatory Class: Class II Product Code: OEO Dated: July 13, 2015 Received: July 14, 2015

Dear Mr. Labiad:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA‚Äôs issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act‚Äôs requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, sMisbranding by reference to premarket notifications (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH‚Äôs Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Reena Philip -S

Reena Philip, Ph.D.   
Director   
Division of Molecular Genetics and Pathology Office of In Vitro Diagnostics and   
Radiological Health   
Center for Devices and Radiological Health

Virtuoso‚Ñ¢ System for IHC PR (1E2) using the VENTANA iScan HT

Indications for Use (Describe)

7KH9LUWXRVR70V\VWHPSURYLGHVDXWRPDWHGGLJLWDOVOLGHFUHDWLRQPDQDJHPHQWDQDO\VLVDQGYLHZLQJ,WLVLQWHQGHGIRU LQYLWURGLDJQRVWLFXVHDVDQDLGWRWKHSDWKRORJLVWLQWKHGLVSOD\GHWHFWLRQFRXQWLQJUHYLHZDQGFODVVLILFDWLRQRIWLVVXHV DQGFHOOVRIFOLQLFDOLQWHUHVWEDVHGRQSDUWLFXODUPRUSKRORJ\FRORULQWHQVLW\VL]HSDWWHUQDQGVKDSH

7KH9LUWXRVR706\VWHPIRU,+&35( XVLQJWKH9(17\$1\$L6FDQ+7LVIRUWKHGLJLWDOUHDGDSSOLFDWLRQ7KLV SDUWLFXODU9LUWXRVRV\VWHPLVLQWHQGHGIRUXVHDVDQDLGWRWKHSDWKRORJLVWLQWKHTXDOLWDWLYHGHWHFWLRQRISURJHVWHURQH UHFHSWRU35SURWHLQLQIRUPDOLQIL[HGSDUDIILQHPEHGGHGQRUPDODQGQHRSODVWLFWLVVXH7KLVGHYLFHLVDQDFFHVVRU\WR 9HQWDQD0HGLFDO6\VWHPV,QF&21),50¬åDQWL3URJHVWHURQH5HFHSWRU35(5DEELW0RQRFORQDO3ULPDU\ \$QWLERG\DVVD\7KH&21),50¬åDQWL3URJHVWHURQH5HFHSWRU35(5DEELW0RQRFORQDO3ULPDU\\$QWLERG\DVVD\ LVLQGLFDWHGIRUXVHDVDQDLGLQWKHDVVHVVPHQWRIEUHDVWFDQFHUSDWLHQWVIRUZKRPHQGRFULQHWUHDWPHQWLVEHLQJ FRQVLGHUHGEXWLVQRWWKHVROHEDVLVIRUWUHDWPHQW

1RWH7KH,+&35('LJLWDO5HDGDSSOLFDWLRQLVDQDGMXQFWLYHFRPSXWHUDVVLVWHGPHWKRGRORJ\IRUWKHTXDOLILHG SDWKRORJLVWLQWKHDFTXLVLWLRQDQGLQWHUSUHWDWLRQRILPDJHVIURPPLFURVFRSHJODVVVOLGHVRIEUHDVWFDQFHUVSHFLPHQV VWDLQHGIRUWKHSUHVHQFHRI35SURWHLQ7KHDFFXUDF\RIWKHWHVWUHVXOWVGHSHQGVRQWKHTXDOLW\RIWKH LPPXQRKLVWRFKHPLFDOVWDLQLQJ,WLVWKHUHVSRQVLELOLW\RIDTXDOLILHGSDWKRORJLVWWRHPSOR\DSSURSULDWHPRUSKRORJLFDO VWXGLHVDQGFRQWUROVDVVSHFLILHGLQWKHLQVWUXFWLRQVIRUWKH&21),50¬åDQWL3URJHVWHURQH5HFHSWRU35(5DEELW 0RQRFORQDO3ULPDU\\$QWLERG\XVHGWRDVVXUHWKHYDOLGLW\RIWKH9LUWXRVR6\VWHPIRU,+&35'LJLWDO5HDGVFRUHV7KH DFWXDOFRUUHODWLRQRI&21),50¬åDQWL35DQWLERG\WRFOLQLFDORXWFRPHKDVQRWEHHQHVWDEOLVKHG7KLVGHYLFHLV LQWHQGHGIRU,+&VOLGHVVWDLQHGRQWKH%HQFK0DUN;7DQG%HQFK0DUN8/75\$VWDLQHUV)RUSUHVFULSWLRQXVHRQO\

# PLEASE DO NOT WRITE BELOW THIS LINE ‚Äì CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

‚ÄúAn agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.‚Äù

# SECTION 5 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is K142965.

807.92 (a)(1): Name: Ventana Digital Pathology Address: 203 Ravendale Rd Mountain View, CA 94043

Phone: (408) 585-7949 FAX: (408) 207-4299 Contact: Mr. Yassine Labiad

807.92 (a)(2): Device name- trade name and common name, and classification

Trade name: Virtuoso‚Ñ¢ System for IHC PR (1E2) using the VENTANA iScan HT

Common Name: IHC Digital pathology system for immunochemistry-stained slides

Classifications: 21 CFR $\$ 864.1860 ‚Äì$ Immunohistochemistry reagents and kits

# 807.92 (a)(3): Identification of the legally marketed predicate devices

This VirtuosoTM System for IHC PR (1E2) using the VENTANA iScan HT is substantially equivalent to its immediate predecessors cleared under K111869 on March 5, 2012, and K122143 on September 19, 2013. The only difference between the two is the use of a new scanner. The new iScan HT scanner is a powerful, high throughput bright field scanner that Ventana Medical Systems has decided to offer as an alternative to the iScan Coreo, which is a low to medium volume instrument currently employed for use with the Virtuoso‚Ñ¢ System for IHC PR (1E2). Both the new and the predicate devices are digital pathology system for the consistent assessment of pathology interpretations using immunohistochemically stained slides (in this case, stained for PR expression), and both systems include slide scanner hardware, and software that both automates the procedural steps and performs the analyses.

# 807.92 (a)(4): Device Description

The Virtuoso‚Ñ¢ System is an instrument-plus-software system designed to assist the qualified pathologist in the consistent assessment of protein expression in immunohistochemically stained histologic sections from formalin-fixed, paraffinembedded normal and neoplastic tissues. The system consists of a slide scanner, computer, monitor, keyboard, and mouse for specific immunohistochemical markers, and software with a Windows web browser-based user interface. Virtuoso is a web-based, end-to-end, digital pathology software solution that allows pathology laboratories to acquire, manage, view, analyze, share, and report digital images of pathology specimens. Using the Virtuoso software, the pathologist can view digital images, add annotations and generate reports.

Hardware: The iScan HT scanning device captures digital images of formalinfixed, paraffin-embedded tissues that are suitable for storage and viewing. The device includes a digital slide scanner, a carousel for loading glass slides, computer, scanner software, keyboard, mouse and monitor.

Software: The Virtuoso software is designed to complement the routine workflow of a qualified pathologist in the review of immunohistochemically stained histologic slides. The software makes no independent interpretations of the data and requires competent human intervention for all steps in the process. Complete software information, following FDA‚Äôs 2005 guidance document for software documentation required for regulatory submissions is being provided in Section 6 of this premarket notification.

# Additional Materials Required:

ÔÇ∑ Ventana CONFIRM‚Ñ¢ anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody   
ÔÇ∑ Reagents for visualization, such as DAB chromogen   
ÔÇ∑ Associated materials for completing immunohistochemical staining according to the appropriate package insert; this submission includes slides stained using both the Benchmark XT and Benchmark ULTRA stainers.   
ÔÇ∑ Color printer if user wishes to print color copies

# Device Quality Control

The quality of results depends on the laboratory following the quality control instructions recommended in the labeling of the immunohistochemistry (IHC) reagents.

# Device Calibration:

The VENTANA iScan HT slide scanner is calibrated and verified at the manufacturing facility before shipment. Upon installation, calibrations are performed and verified by Roche Customer Support. No additional calibration or verification is required or performed by the end user. Annual preventive maintenance performed by Roche Customer Support is recommended to ensure that the VENTANA iScan HT slide scanner is operating as intended.

# Summary of Procedure

Samples are obtained as formalin-fixed, paraffin-embedded tissue blocks. Histologic sections are prepared and mounted onto glass slides. Slides are reacted with the PR (1E2) primary antibody and are then visualized using DAB. Prepared slides are loaded into the Virtuoso system scanner and scanned. The resulting digital images are reviewed by the pathologist on a computer monitor.

# 807.92 (a)(5): Intended Use

The VirtuosoTM system provides automated digital slide creation, management, analysis, and viewing. It is intended for in vitro diagnostic use as an aid to the pathologist in the display, detection, counting, review and classification of tissues and cells of clinical interest based on particular morphology, color, intensity, size, pattern and shape.

The VirtuosoTM System for IHC PR (1E2) using the VENTANA iScan HT is for the digital read application. This particular Virtuoso system is intended for use as an aid to the pathologist in the qualitative detection of progesterone receptor (PR) protein in formalin-fixed, paraffin-embedded normal and neoplastic tissue. This device is an accessory to Ventana Medical Systems, Inc. CONFIRM‚Ñ¢ antiProgesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody assay. The CONFIRM‚Ñ¢ anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody assay is indicated for use as an aid in the assessment of breast cancer patients for whom endocrine treatment is being considered (but is not the sole basis for treatment).

Note: The IHC PR (1E2) Digital Read application is an adjunctive computerassisted methodology for the qualified pathologist in the acquisition and interpretation of images from microscope glass slides of breast cancer specimens stained for the presence of PR protein. The accuracy of the test results depends on the quality of the immunohistochemical staining. It is the responsibility of a qualified pathologist to employ appropriate morphological studies and controls as specified in the instructions for the CONFIRM‚Ñ¢ anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody used to assure the validity of the Virtuoso System for IHC PR Digital Read scores. The actual correlation of CONFIRM‚Ñ¢ anti-PR antibody to clinical outcome has not been established. This device is intended for IHC slides stained on the BenchMark XT and BenchMark ULTRA stainers. For prescription use only.

# 807.92 (a)(6): Technological Similarities and Differences to the Predicate Devices

The similarities and differences between the two test systems are described below.

<table><tr><td>Characteristic</td><td>Predicate 1 VirtuosoTM System for IHC PR (1E2) [Benchmark ULTRA Stainer]</td><td>Predicate 2 VirtuosoTM System for IHC PR (1E2)</td><td>New Device VirtuosoTM System for IHC PR (1E2) Using the VENTANA iScan</td></tr><tr><td rowspan="2">Intended Use/Indications for Use</td><td>K122143 The Virtuoso System provides automated digital slide creation, management, analysis, and viewing. It is intended for IVD use as an aid to the pathologist in the display, detection, counting, review and classification of tissues and cells of clinical interest based on particular morphology, color, size, intensity, pattern and shape. The VirtuosoTM System for IHC PR (1E2) is for digital read and image analysis applications. This particular Virtuoso system is intended for use as an aid to the pathologist in the detection and semi-quantitative measurement of progesterone receptor (PR) protein in formalin-fixed, paraffin-embedded normal and neoplastic tissue. This device is an accessory to Ventana Medical Systems, Inc. CONFIRMTM anti- Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody assay. The CONFIRMTM anti-Progesterone</td><td>[Benchmark XT Stainer] K111869 SAME SAME</td><td>HT The Virtuoso system provides automated digital slide creation, management, analysis, and viewing. It is intended for in vitro diagnostic use as an aid to the pathologist in the display, detection, counting, review and classification of tissues and cells of clinical interest based on particular morphology, color, intensity, size, pattern and shape. The Virtuoso‚Ñ¢ System for IHC PR (1E2) using the VENTANA iScan HT is for the digital read application. This particular Virtuoso system is intended for use as an aid to the pathologist</td></tr><tr><td>Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody assay is indicated for use as an aid in the assessment of breast cancer patients for whom endocrine treatment is being considered (but is not the sole basis for treatment). Note: The IHC PR (1E2) Digital Read and Image Analysis applications are adjunctive computer- assisted</td><td></td><td>in the qualitative detection of progesterone receptor (PR) protein in formalin-fixed, paraffin-embedded normal and neoplastic tissue. This device is an accessory to Ventana Medical Systems, Inc. CONFIRMTM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody assay. The CONFIRMTM anti- Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody assay is indicated for use as an aid in the assessment of breast cancer patients for whom endocrine treatment is being considered (but is not the sole basis for treatment). Note: The IHC PR (1E2)</td></tr><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">Predicate 1VirtuosoTM System for IHC PR(1E2)[Benchmark ULTRA Stainer]K122143</td><td colspan="1" rowspan="1">Predicate 2VirtuosoTM System forIHC PR (1E2)[Benchmark XT Stainer]K111869</td><td colspan="1" rowspan="1">New DeviceVirtuosoTM System for IHCPR (1E2)Using the VENTANA iScanHT</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">methodologies for the qualifiedpathologist in the acquisition andmeasurement of images frommicroscope glass slides of breastcancer specimens stained for thepresence of PR protein. Thepathologist should verifyagreement with the ImageAnalysis software applicationscore. The accuracy of the testresults depends on the quality ofthe immunohistochemicalstaining. It is the responsibilityof a qualified pathologist toemploy appropriatemorphological studies andcontrols as specified in theinstructions for theCONFIRMTM anti-ProgesteroneReceptor (PR) (1E2) RabbitMonoclonal Primary Antibodyused to assure the validity of theVirtuoso System for IHC PRDigital Read and Image Analysisscores. The actual correlation ofCONFIRMTM anti-PR antibodyto clinical outcome has not beenestablished. This device isintended for IHC slides stainedon the BenchMark XT andBenchMark ULTRA stainers.For prescription use only.</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Digital Read application is anadjunctive computer-assistedmethodology for the qualifiedpathologist in the acquisitionand interpretation of imagesfrom microscope glass slides ofbreast cancer specimens stainedfor the presence of PR protein.The accuracy of the test resultsdepends on the quality of theimmunohistochemical staining.It is the responsibility of aqualified pathologist to employappropriate morphologicalstudies and controls asspecified in the instructions forthe CONFIRMTM anti-Progesterone Receptor (PR)(1E2) Rabbit MonoclonalPrimary Antibody used toassure the validity of theVirtuoso System for IHC PRDigital Read score. The actualcorrelation of CONFIRMTManti-PR antibody to clinicaloutcome has not beenestablished. This device isintended for IHC slides stainedon the BenchMark XT andBenchMark ULTRA stainers.For prescription use only.</td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">Formalin-fixed, paraffin-embedded tissue stained byimmunohistochemical technique</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">System Operation(Digital Read andImage Analysis)</td><td colspan="1" rowspan="1">Histologic observation by apathologist through the imageviewer and image analysissystems</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Histologic observation by apathologist through the imageviewer system.</td></tr><tr><td colspan="1" rowspan="1">Hardware andSoftware</td><td colspan="1" rowspan="1">Ventana iScan slide scanner,computer, color monitor,proprietary software for PR(1E2)</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Ventana iScan HT scanner,computer, color monitor,proprietary software for PR(1E2)</td></tr><tr><td colspan="1" rowspan="1">Platform</td><td colspan="1" rowspan="1">Mouse, keyboard, windows web</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Components</td><td colspan="1" rowspan="1">browser.</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Primary Antibody(Assay) Reagent</td><td colspan="1" rowspan="1">Ventana CONFIRMTM anti-Progesterone Receptor (PR)(1E2) Rabbit MonoclonalPrimary Antibody</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">AncillaryReagents/Stainers</td><td colspan="1" rowspan="1">DAB universal chromogen kits,Slides stained with BenchmarkULTRA stainer</td><td colspan="1" rowspan="1">DAB universal chromogenkits, slides stained withBenchmark XT stainer</td><td colspan="1" rowspan="1">DAB universal chromogen kits,slides stained with BenchmarkXT and ULTRA stainers</td></tr><tr><td colspan="1" rowspan="1">Localization ofIHC positive stain</td><td colspan="1" rowspan="1">Nucleus</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Interpretation</td><td colspan="1" rowspan="1">Interpretation is performed bythe pathologist.</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr></table>

# 807.92 (b)(1/2): Brief Description of Clinical Data (Non-clinical data N/A)

The VirtuosoTM System for IHC PR (1E2) using the VENTANA iScan HT was clinically validated via a method comparison (agreement/concordance) study and a precision and reproducibility study. The method comparison study evaluated overall system performance in terms of agreement between the reference manual method (with a traditional microscope) and the digital read (DR) application of the Virtuoso system. Two sets of statistical analyses were performed for the method comparison study: 1) Initial analysis: This analysis involved the primary endpoint analysis for each of the 3 pathologists participating in the study. The primary end points included the overall percent agreement (OPA), positive percent agreement (PPA), and negative percent agreement (NPA) between the Digital Read (DR) method and Manual Read (MR) method. 2) The additional analysis employed the Generalized Linear Mixed Model (GLMM) analysis methodology for the primary endpoint analysis. This additional analysis was associated with model-based results, which enabled appropriate estimation within a repeated-measures design of the average reader performance using the comparator device. The GLMM analysis included all 3 pathologists‚Äô data.

The reproducibility components of the studies involved the intrapathologist/inter-day reproducibility evaluation as well the inter-pathologist reproducibility of the DR Virtuoso application.

The Scanner precision study involved a subset of the clinical cases $[ \mathfrak { n } = 4 0$ , both stainers) that were scanned two more times, and also scanned three times with two different scanners at two separate locations. This study evaluated scanner precision for both inter-scanner precision and intra-scanner/inter-day precision.

The data from both method comparison and precision/reproducibility studies are summarized below.

# Method comparison (Agreement/Concordance)

Virtuoso Digital Read vs Manual Method

Each pathologist‚Äôs Virtuoso digital read results were compared to their manual results. The data were categorized as ‚Äúneg‚Äù and ‚Äúpos‚Äù using the PR score of 0 to $0 . 9 9 \%$ positive staining to describe negative, and $2 1 \%$ positive staining to describe positive. The overall percent agreements using negative and positive, as defined above, across the three sites were: $9 8 . 7 \%$ , $8 8 . 9 \%$ , and $9 6 . 2 \%$ , respectively. The overall, negative, and positive percent agreements, with the $9 5 \%$ confidence intervals (CI) around the agreements are shown below.

Table: PR Clinical Status Agreement[a,b] Between DR and MR[c], By Site (Reader)   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=8>Manual Read</td></tr><tr><td rowspan=1 colspan=2>SITE 1(n =159)Pos  Neg</td><td rowspan=1 colspan=2>SITE 2(n =162)Pos  Neg</td><td rowspan=1 colspan=2>SITE 3(n =156)Pos  Neg</td><td rowspan=1 colspan=2>Overall(n = 477)Pos    Neg</td></tr><tr><td rowspan=3 colspan=1>Digital Read</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>247</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>204</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>265</td><td rowspan=1 colspan=1>212</td></tr><tr><td rowspan=1 colspan=2>Overall agreement (%)(95% CI)[d]</td><td rowspan=1 colspan=2>98.7(95.5-99.7)</td><td rowspan=1 colspan=2>88.9(83.1-92.9)</td><td rowspan=1 colspan=2>96.2(91.9-98.2)</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=2>Positive Agreement (%)(95% CI) </td><td rowspan=1 colspan=2>99.1(94.9-99.8)</td><td rowspan=1 colspan=2>86.7(77.8-92.4)</td><td rowspan=1 colspan=2>91.9(83.4-96.2)</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=2>Negative agreement (%)(95% C1) (dj</td><td rowspan=1 colspan=2>98.0(89.7-99.7)</td><td rowspan=1 colspan=2>91.1(82.8-95.6)</td><td rowspan=1 colspan=2>100.0(95.5-100.0)</td><td rowspan=1 colspan=2></td></tr></table>

[a] Clinical status: positive $=$ clinical scoring category of $1 - 1 0 \%$ or ${ > } 1 0 \%$ ; negative $=$ clinical scoring category of $0 { - } 0 . 9 9 \%$ . [b] Only cases with evaluable results are included this analysis. For a case result to be evaluable, the investigator must have assigned a valid clinical score (status) to the case and must have confirmed that the case morphology and background staining were acceptable and that the run controls were valid. [c] For sites that performed two independent MR scoring rounds, these data are from the first MR round. [d] Two-sided 95% confidence interval calculated using the score method.

# Reproducibility

a. Intra-Pathologist/Inter-Day (pair-wise comparisons, Session 1 vs Session 2, Session 1 vs Session 3, Session 2 vs Session 3)

# Digital Read

In the primary analysis of DR intra-reader reproducibility, the PR clinical status [negative $( 0 { - } 0 . 9 9 \% )$ or positive $( \geq 1 \% ) ]$ was compared across three individual DR evaluations of the same set of 39 cases by the Reader. The $2 \times$ 2 comparisons for the 3 reading sessions (reads) are shown in the following table with the respective agreement values. OPA rates for the 3 pairwise comparisons ranged from $8 9 . 7 \%$ to $9 7 . 4 \%$ . During the second and third reads for the DR reproducibility evaluation, Reader 3 investigator identified one case as unevaluable.

PR clinical Status [a] Agreement Within Reader (Digital Read)   

<table><tr><td rowspan="4">READ 1 vS READ 2 Read 1 Clinical Assessment</td><td></td><td>Read 2 Clinical Assessment</td><td></td><td>Read 1 vs Read 2 Agreement Rates</td><td></td><td></td></tr><tr><td></td><td>Pos Neg</td><td>Total</td><td>Rate n/N</td><td>%</td><td>95% Cl[b]</td></tr><tr><td>Pos</td><td>19</td><td>1 20</td><td>APA 38/39</td><td>97.4</td><td>90.9-100.0</td></tr><tr><td>Neg</td><td>0 19</td><td>19</td><td>ANA</td><td>38/39 97.4</td><td>90.7-100.0</td></tr><tr><td rowspan="5">READ 1 vS READ 3 Read 1 Clinical Assessment</td><td>Total</td><td>19 Read 3 Clinical Assessment</td><td>20 39</td><td>OPA 38/39</td><td>97.4 Read 1 vs Read 3 Agreement Rates</td><td>86.8-99.5</td></tr><tr><td></td><td>Pos Neg</td><td>Total</td><td>Rate n/N</td><td>%</td><td>95% Clb</td></tr><tr><td>Pos</td><td>18</td><td>2 20</td><td>APA</td><td>36/40 90.0</td><td>78.0-97.9</td></tr><tr><td>Neg</td><td>2</td><td>17 19</td><td>ANA</td><td>34/38 89.5</td><td>76.5-97.8</td></tr><tr><td>Total</td><td>20 19</td><td>39</td><td>OPA</td><td>35/39 89.7</td><td>76.4-95.9</td></tr><tr><td rowspan="2">READ 2 vs READ 3</td><td></td><td>Read 3 Clinical Assessment</td><td></td><td></td><td>Read 2 vs Read 3 Agreement Rates</td><td></td></tr><tr><td></td><td>Pos Neg</td><td>Total</td><td>Rate</td><td>n/N %</td><td>95% Clb]</td></tr><tr><td rowspan="4">Read 2 Clinical Assessment</td><td>Pos</td><td>18</td><td>1 19</td><td>APA</td><td>36/39 92.3</td><td>81.3-100.0</td></tr><tr><td>Neg</td><td>2</td><td>18 20</td><td>ANA</td><td>36/39 92.3</td><td>81.3-100.0</td></tr><tr><td>Total</td><td>20</td><td>39</td><td>OPA</td><td>36/39</td><td></td></tr><tr><td>l   inl s  l </td><td></td><td>19</td><td></td><td>92.3</td><td>79.7-97.3</td></tr></table>

b. Inter-Pathologist (pair-wise comparisons, Pathologist 1 vs Pathologist 2, Pathologist 1 vs Pathologist 3, Pathologist 2 vs Pathologist 3)

The agreement of PR clinical status between sites (readers) was examined separately for DR and MR. Each investigator‚Äôs results for the PR clinical status [negative $( 0 { - } 0 . 9 9 \% )$ or positive $( \geq 1 \% ) ]$ of the study cases were compared to those of another reader using the same reading method. The agreement rates and $9 5 \%$ CIs are shown in the following tables, respectively, for each reading method (DR and MR).

# Manual Read

The three manual readings across the three pathologists (sites) were compared to each other. The reproducibility in the manual readings among the three pathologists (sites) is shown below, along with the $9 5 \%$ CIs. The OPA rates for the 3 pairwise comparisons ranged from $8 1 . 0 \%$ to $9 2 . 9 \%$ .

PR Clinical Status Agreement[a,b] Between Sites (Readers) : Manual Read   

<table><tr><td colspan="2" rowspan="2">SITE 1 vS. SITE 2</td><td rowspan="2"></td><td colspan="2">Site 2 Clinical Assessment</td><td colspan="4">Site 1-vs-Site 2 Agreement Rates</td></tr><tr><td>Pos</td><td>Neg</td><td>Total</td><td>Rate</td><td>n/N</td><td>% 95% CI (d (%)</td></tr><tr><td rowspan="3">Site 1 Clinical Assessment</td><td>Pos</td><td>82</td><td>25</td><td>107</td><td>APA</td><td>164/190</td><td>86.3</td><td>80.7-91.2</td></tr><tr><td>Neg</td><td>1</td><td>50</td><td>51</td><td></td><td>ANA</td><td>100/126 79.4</td><td>71.1-86.6</td></tr><tr><td>Total</td><td>83</td><td>75</td><td>158</td><td></td><td>OPA</td><td>132/158 83.5</td><td>77.0-88.5</td></tr><tr><td colspan="2" rowspan="2">SITE 1 vs. SITE 3</td><td colspan="2"></td><td>Site 3</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Clinical Assessment Pos Neg</td><td></td><td>Total</td><td>Rate</td><td>%</td><td>Site 1-vs-Site 3 Agreement Rates</td></tr><tr><td rowspan="3">Site 1 Clinical Assessment</td><td>Pos</td><td>74</td><td>29</td><td>103</td><td>APA</td><td>n/N 148/177</td><td>83.6</td><td>95% CI [d (%) 77.2-89.4</td></tr><tr><td>Neg</td><td>0</td><td>50</td><td>50</td><td>ANA</td><td>100/129</td><td>77.5</td><td>68.8-85.1</td></tr><tr><td>Total</td><td>74</td><td>79</td><td>153</td><td>OPA</td><td>124/153</td><td>81.0</td><td></td></tr><tr><td colspan="2" rowspan="2">SITE 2 vs. SITE 3</td><td></td><td>Site 3</td><td></td><td></td><td></td><td></td><td></td><td>74.1-86.5</td></tr><tr><td></td><td>Clinical Assessment</td><td></td><td></td><td></td><td></td><td>Site 2-vs-Site 3 Agreement Rates</td><td></td></tr><tr><td rowspan="3">Site 2 Clinical Assessment</td><td></td><td>Pos</td><td>Neg</td><td></td><td>Total</td><td>Rate</td><td>n/N</td><td>%</td><td>95% CI d (%)</td></tr><tr><td>Pos</td><td>70</td><td>8</td><td>78</td><td></td><td>APA</td><td>140/151</td><td>92.7</td><td>88.0-96.7</td></tr><tr><td>Neg Total</td><td>3 73</td><td>74 82</td><td>155</td><td>77</td><td>ANA OPA</td><td>148/159 144/155</td><td>93.1 92.9</td><td>88.6-96.8 87.7-96.0</td></tr></table>

[a] Clinical status: positive $=$ clinical scoring category of $1 - 1 0 \%$ or $\geq 1 0 \%$ ; negative $=$ clinical scoring category of $0 - 0 . 9 9 \%$ .

[b] Only cases with evaluable results are included this analysis. For a case result to be evaluable, the investigator must have assigned a valid clinical score (status) to the case and must have confirmed that the case morphology and background staining were acceptable and that the run controls were valid.

[c] Two-sided $9 5 \%$ confidence interval for OPA of each site (reader) pair (not pooled for all sites) are calculated using the score method. The other CIs are calculated using the percentile bootstrap method.

# Digital Read

The reproducibility in the Virtuoso digital readings among the three pathologists (sites) is shown below, along with the $9 5 \%$ CIs. The overall percent agreements ranged from $7 7 . 4 \%$ to $8 9 . 9 \%$ .

PR Clinical Status Agreement[a,b] Between Sites (Readers): Digital Read   

<table><tr><td colspan="2" rowspan="2">SITE 1 vS. SITE 2</td><td colspan="3">Site 2 Clinical Assessment</td><td colspan="4">Site 1-vs-Site 2 Agreement Rates</td></tr><tr><td>Pos</td><td>Neg</td><td>Total</td><td>Rate</td><td>n/N</td><td>95% CI (d (%) %</td></tr><tr><td rowspan="3">Site 1 Clinical Assessment</td><td>Pos</td><td>79</td><td>29</td><td>108</td><td>APA</td><td>158/188 84.0</td><td>78.0-89.6</td></tr><tr><td>Neg</td><td>1</td><td>50</td><td>51</td><td>ANA</td><td>100/130 76.9</td><td>68.8-84.6</td></tr><tr><td>Total</td><td>80</td><td>79</td><td>159</td><td>OPA</td><td>129/159 81.1</td><td>74.3-86.5</td></tr><tr><td colspan="2">SITE 1 vs. SITE 3</td><td colspan="7">Site 3 Clinical Assessment Site 1-vs-Site 3 Agreement Rates</td></tr><tr><td colspan="2"></td><td>Pos</td><td>Neg</td><td>Total</td><td>Rate</td><td>n/N</td><td>%</td><td>95% CI d (%)</td></tr><tr><td rowspan="3">Site 1 Clinical Assessment</td><td>Pos</td><td>70</td><td>35</td><td>105</td><td>APA</td><td>140/175</td><td>80.0</td><td>73.4-86.3</td></tr><tr><td>Neg</td><td>0</td><td>50</td><td>50</td><td>ANA</td><td>100/135</td><td>74.1</td><td>65.6-81.8</td></tr><tr><td>Total</td><td>70</td><td>85</td><td>155</td><td>OPA</td><td>120/155</td><td>77.4</td><td>70.2-83.3</td></tr><tr><td colspan="2">SITE 2 vs. SITE 3 Clinical Assessment</td><td></td><td></td><td>Site 3</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2"></td><td>Pos</td><td>Neg</td><td></td><td>Total</td><td>Rate</td><td>n/N %</td><td>Site 2-vs-Site 3 Agreement Rates</td><td>95% CI d (%)</td></tr><tr><td rowspan="3">Site 2 Clinical Assessment</td><td>Pos</td><td></td><td></td><td></td><td>76</td><td>APA</td><td>130/146 89.0</td><td></td><td>83.5-93.8</td></tr><tr><td>Neg</td><td>65 5</td><td>11 77</td><td></td><td>82</td><td>ANA</td><td>154/170 90.6</td><td></td><td>85.7-94.7</td></tr><tr><td>Total</td><td>70</td><td>88</td><td></td><td>158</td><td>OPA</td><td>142/158 89.9</td><td></td><td>84.2-93.7</td></tr></table>

[a] Clinical status: positive $=$ clinical scoring category of $1 - 1 0 \%$ or $\geq 1 0 \%$ ; negative $=$ clinical scoring category of $0 - 0 . 9 9 \%$ .

[b] Only cases with evaluable results are included this analysis. For a case result to be evaluable, the investigator must have assigned a valid clinical score (status) to the case and must have confirmed that the case morphology and background staining were acceptable and that the run controls were valid.

[c] Two-sided $9 5 \%$ confidence interval for OPA of each site (reader) pair (not pooled for all sites) are calculated using the score method. The other CIs are calculated using the percentile bootstrap method.

# Scanner Precision

Forty (40) cases representing the useful categories of ${ < } 1 \%$ , $1 - 1 0 \%$ , and $10 \%$ positive staining for PR were scanned on three different scanners at three different sites to assess inter-scanner precision, and three FOVs were captured (t $\mathbf { o t a l } = 1 2 0 $ ) and evaluated. Similarly, these same 40 cases were scanned on three different days by the same scanner, and the same FOVs were applied to the appropriate cases to assess intra-scanner/inter day precision.

Pairwise comparisons were performed between each of the three sites (interscanner), and between each of the three days (sessions, intra-scanner). The precision tables are found below.

# PR Clinical Scoring Category [a] Agreement Between Scanners (Between Sites): All FOVs Combined

<table><tr><td rowspan="2">SITE 1 vS SITE 2 []</td><td colspan="4">Site 2 Clinical Scoring Category</td><td colspan="3">OPA</td></tr><tr><td>&gt;10%</td><td>1-10%</td><td>0-0.99%</td><td>Total</td><td>n/N</td><td>%</td><td>95% Clc]</td></tr><tr><td rowspan="4">Site 1 Clinical Scoring Category</td><td>&gt;10% 3</td><td>113 8</td><td>0</td><td>121</td><td rowspan="4">324/360</td><td>90.0</td><td>86.5-92.7</td></tr><tr><td>1-10%</td><td>30</td><td>15</td><td>48</td><td></td><td></td></tr><tr><td>0-0.99% 0</td><td>10</td><td>181</td><td>191</td><td></td><td></td></tr><tr><td>Total 116</td><td>48</td><td>196</td><td>360</td><td></td><td></td></tr><tr><td colspan="2">SITE 1 vS SITE 3 []</td><td colspan="4">Site 3 Clinical Scoring Category</td><td>OPA</td><td></td><td></td></tr><tr><td colspan="2" rowspan="2">&gt;10% Site 1 Clinical Scoring</td><td>&gt;10%</td><td>1-10% 0</td><td>0-0.99%</td><td>Total 121</td><td>n/N % 337/360</td><td>95% Cicl</td></tr><tr><td colspan="4">119 2</td><td rowspan="6"></td><td rowspan="6">93.6 90.6-95.7</td></tr><tr><td rowspan="3">Category Total</td><td rowspan="3">1-10% 4 0-0.99% 0</td><td>34</td><td>10</td><td>48</td></tr><tr><td>7</td><td>184 191</td><td></td></tr><tr><td>123 43</td><td>194 Site 3 Clinical Scoring Category</td><td>360</td></tr><tr><td colspan="2" rowspan="2">SITE 2 vS SITE 3 [b]</td><td colspan="3">&gt;10% 0-0.99%</td><td rowspan="2">OPA Total n/N</td><td>%</td></tr><tr><td>1-10%</td><td></td><td>325/360 90.3</td></tr><tr><td rowspan="4">Site 2 Clinical Scoring Category</td><td rowspan="2">&gt;10% 1-10%</td><td>115 1</td><td></td><td>0</td><td>116</td><td rowspan="4"></td><td rowspan="4">86.8-92.9</td></tr><tr><td>8</td><td>28</td><td>12</td><td>48</td></tr><tr><td>0-0.99%</td><td>0</td><td>14 182</td><td>196</td></tr><tr><td>Total</td><td>123</td><td>43</td><td>194</td><td>360</td></tr><tr><td colspan="7">[a) pR clinical scoring categories of: 0 - 0.99% (negative), 110% (positive), and ‚â• 10% (positive). This analysis is based on the results of pooling alldays. sided 95% Cls for OPA f each sie (reade) pair (not poole or allse-pair) are calculat using the score method. Two-sided 95% Cls for OPA with all site-pairs pooled are calculated using the percentile bootstrap method.</td></tr></table>

# PR Clinical Scoring Category [a] Agreement Within Scanners (Between Days): All FOVs Combined

<table><tr><td rowspan="2">DAY 1 vS DAY 2 [b]</td><td colspan="4">Day 2 Clinical Scoring Category</td><td colspan="3">OPA</td></tr><tr><td>&gt;10%</td><td>1-10%</td><td>0-0.99%</td><td>Total</td><td>n/N</td><td>%</td><td>95% Cilc</td></tr><tr><td rowspan="3">&gt;10% Day 1 Clinical Scoring 1-10% Category Total</td><td>117 1 1</td><td>4 33</td><td>0 11</td><td>121 45</td><td>332/360</td><td></td><td>92.2 89.0-94.6</td></tr><tr><td>0-0.99% 119</td><td>11 48</td><td>182 193</td><td>194 360</td><td></td><td></td><td></td></tr><tr><td colspan="3">Day 3 Clinical Scoring Category &gt;10%</td><td>Total</td><td>OPA</td><td>%</td><td>95% Cic]</td></tr><tr><td rowspan="2">Day 1 Clinical Scoring Category Total</td><td rowspan="2">&gt;10% 118 1-10% 2 0-0.99% 0</td><td>1-10% 3</td><td>0-0.99% 0 14</td><td>121</td><td>n/N 327/360</td><td></td><td>90.8 87.4-93.4</td></tr><tr><td>29 14 120 46</td><td>180 194</td><td>45 194 360</td><td></td><td></td><td></td></tr><tr><td colspan="2">DAY 2 vS DAY 3 [b]</td><td colspan="4">Day 3 Clinical Scoring Category &gt;10% 1-10%</td><td>OPA n/N %</td><td>95% Cilc</td></tr><tr><td rowspan="4">Day 2 Clinical Scoring Category Total</td><td rowspan="4">&gt;10% 1-10% 0-0.99%</td><td>115 3</td><td>1</td><td>0-0.99%</td><td>Total 119</td><td>327/360</td><td>90.8 87.4-93.4</td></tr><tr><td>5</td><td>31</td><td>12</td><td>48</td><td></td><td></td></tr><tr><td>0</td><td>12</td><td>181</td><td>193</td><td></td><td></td></tr><tr><td>120 46</td><td></td><td>194</td><td>360</td><td></td><td></td></tr><tr><td colspan="7">(al pR clinical scoring categories of: 0 - 0.99% (negative), 110% (positive), and ‚â• 10% (positive).    . cTo-sided 95% Cs for OPA of each day pair (not pooled for ll day-pairs) are calculated using the score method. Two-sided 95% Cls for OPA with all day-pairs pooled are calculated using the percentile bootstrap method.</td></tr></table>

# 807.92 (b)(3): Conclusions from Clinical Testing

Concordance, reproducibility, and precision studies were performed for the Virtuoso System for IHC PR (1E2) using the VENTANA iScan HT. The test system was shown to be as safe and effective (therefore substantially equivalent) as the predicate devices for its intended use.